Chemo-immunotherapy in RCC: the end of a story (Q43155982)

14 November 2017

title

Chemo-immunotherapy in RCC: the end of a story (English)

1 reference

14 November 2017

1 reference

Bernard Escudier

1 reference

14 November 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

14 November 2017

1 reference

14 November 2017

volume

375

1 reference

14 November 2017

issue

9715

1 reference

14 November 2017

page(s)

613-614

1 reference

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960209-7

7 January 2021

10.1016/S0140-6736(10)60209-7

Identifiers

DOI

1 reference

14 November 2017

1 reference